טוען...
Efficacy and Safety of Edoxaban in Patients With Active Malignancy and Atrial Fibrillation: Analysis of the ENGAGE AF‐TIMI 48 Trial
BACKGROUND: Anticoagulation in patients with malignancy and atrial fibrillation is challenging because of enhanced risks for thrombosis and bleeding and the frequent need for invasive procedures. Data on direct oral antagonists in such patients are sparse. METHODS AND RESULTS: The ENGAGE AF‐TIMI 48...
שמור ב:
| הוצא לאור ב: | J Am Heart Assoc |
|---|---|
| Main Authors: | , , , , , , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
John Wiley and Sons Inc.
2018
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6201390/ https://ncbi.nlm.nih.gov/pubmed/30369307 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/JAHA.118.008987 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|